ESTRELLA CADDALI: Open Payments
NPI 1164974580 · HONOLULU, HI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$768 in 18 payments from 11 companies in 2025. Trend: 2023 $721 · 2024 $635 · 2025 $768
Food & beverage: $768
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 2 | $225 |
| Alkermes, Inc. | 1 | $126 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $121 |
| ABBVIE INC. | 3 | $73 |
| Novo Nordisk Inc | 4 | $70 |
| Lilly USA, LLC | 2 | $39 |
| Astellas Pharma US Inc | 1 | $31 |
| Amgen Inc. | 1 | $24 |
| Aimmune Therapeutics, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
Products named: COBENFY, LYBALVI, CAPLYTA, MOUNJARO, Wegovy, Veozah, VRAYLAR, MAVYRET.
Industry payments across HI — which companies pay providers there.
